Please assess the completion status of the following clinical trial:

Trial Title: Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Eligibility Criteria:~* Cytologically or histologically confirmed COX dependent non-small cell lung cancer.~* COX dependency is defined by change in urinary PGE-M levels following a run-in phase of celecoxib.~* Previous treatment with ≤2 different chemotherapy regimens one of which must have been platinum-based (cisplatin or carboplatin) chemotherapy.~* Age ≥18 years~* ECOG PS 0, 1 or 2.~* Measurable or evaluable disease.~* At least 3 weeks post major surgery, chemotherapy or radiotherapy \& recovered from all toxicities.~* Expected survival of at least 2 months.~* CNS metastases permitted provided the patient has adequately recovered from radiotherapy includes stereotactic therapy) or surgery.~* Adequate renal function: serum creatinine ≤1.8 mg/dl \&/or CrCl \>50 cc/min~Eligibility According to Liver Function:~AST:~\</= 1.5 ULN-Docetaxel; \</= 2.5 ULN-Pemetrexed (Liver parameters to be used for pemetrexed in the absence of proven or radiographically suspected liver metastases.); \</= 5.0 ULN-Pemetrexed (Liver parameters to be used for pemetrexed only in the presence of proven or radiographically suspected liver metastases.)~Alk Phosphatase:~\</= 2.5 ULN-Docetaxel; \</= 2.5 ULN-Pemetrexed (Liver parameters to be used for pemetrexed in the absence of proven or radiographically suspected liver metastases.); \</= 5.0 ULN-Pemetrexed (Liver parameters to be used for pemetrexed only in the presence of proven or radiographically suspected liver metastases.)~Total Bilirubin:~\</= 1.5 ULN-Docetaxel; \</= 1.5 ULN-Pemetrexed (Liver parameters to be used for pemetrexed in the absence of proven or radiographically suspected liver metastases.); \</= 2.5 ULN-Pemetrexed (Liver parameters to be used for pemetrexed only in the presence of proven or radiographically suspected liver metastases.)~* Adequate hematologic function: ANC≥1500/mm3 \& platelets ≥100,000/mm3~* Female patients cannot be pregnant and must use contraception if of childbearing age~* Lactating women are excluded.~* Peripheral neuropathy must be CTC grade ≤2~* Patients must not currently be on non-steroidal anti-inflammatory agents or other COX-2 inhibitors (Must be off for at least ≤7 days)~* Written informed consent.~Exclusion Criteria:~* More than two prior chemotherapy regimens for recurrent or relapsed NSCLC.~* COX Independent as defined by change in urinary PGE-M levels following a run-in phase of celecoxib.~* Previous treatment with both docetaxel and pemetrexed~* History of greater than grade 2 allergic reaction to celecoxib or any other non-steroid anti-inflammatory agent including aspirin, ibuprofen, or indomethacin.~* History of allergy to compounds containing boron or mannitol.~* History of allergy to sulfonamides.~* Concomitant use of Warfarin, but low dose Coumadin allowed for port prophylaxis~* Recent (past 4 weeks) coronary artery bypass graft (CABG) surgery.~* Inadequate organ function:~* Serum creatinine ≥1.8 mg/dl or a calculated CrCl \<45 cc/min.~* AST \>1.5 upper limits of normal (ULN); alkaline phosphatase \>2.5 ULN; \& bilirubin \>1.5 ULN~* ANC\<1500/mm3 \& platelets \<100,000/mm3~* Active pregnancy or inability or unwillingness to employ appropriate contraception.~* Small cell carcinoma histology.~* Prior malignancy within 5 years of diagnosis of NSCLC. Exceptions include basal cell or non-metastatic squamous cell carcinomas of the skin, cervical carcinoma in situ or FIGO stage I cervical carcinoma, or other cancer history considered not clinically significant by the principal investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Either docetaxel or pemetrexed given with celecoxib

Based on this trial design, predict the completion outcome and termination type (if applicable).